Loading...
Docoh

Sierra Oncology (SRRA)

News

From Benzinga Pro
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
17 Jun 22
Biotech, Large Cap, News, Penny Stocks, Health Care, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Sierra Oncology's Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting On June 7, 10:33 a.m.
26 May 22
Biotech, News, Events, General
Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the
Recap: Sierra Oncology Q1 Earnings
6 May 22
Earnings, News
Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Sierra Oncology Q1 EPS $(1.33) Up From $(1.46) YoY
6 May 22
Earnings, News
Sierra Oncology (NASDAQ:SRRA) reported quarterly losses of $(1.33) per share. This is a 8.9 percent increase over losses of $(1.46) per share from the same period last year.
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
17 Apr 22
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, General
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting season.
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
14 Apr 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Analyst Ratings for Sierra Oncology
14 Apr 22
Analyst Ratings
Sierra Oncology (NASDAQ:SRRA) has observed the following analyst ratings within the last quarter:
Analyzing Sierra Oncology Inc's Short Interest
14 Apr 22
Short Sellers, Short Ideas, Trading Ideas
Sierra Oncology Inc's (NASDAQ:SRRA) short percent of float has fallen 10.32% since its last report. The company recently reported that it has 1.21 million shares sold short, which is 11.91% of all regular shares that are available for trading.
Jefferies Downgrades Sierra Oncology to Hold, Raises Price Target to $55
14 Apr 22
News, Downgrades, Price Target, Analyst Ratings
Jefferies analyst Maury Raycroft downgrades Sierra Oncology (NASDAQ:SRRA) from Buy to Hold and raises the price target from $39 to $55.
Oppenheimer Downgrades Sierra Oncology to Perform, Raises Price Target to $55
14 Apr 22
News, Downgrades, Price Target, Analyst Ratings
Oppenheimer analyst Jay Olson downgrades Sierra Oncology (NASDAQ:SRRA) from Outperform to Perform and raises the price target from $45 to $55.
12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Apr 22
Movers
Gainers
Sierra Oncology Stock Is Soaring: Here's Why
13 Apr 22
M&A, Small Cap, Movers, Trading Ideas
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in cash, representing an a
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
13 Apr 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
HC Wainwright & Co. Downgrades Sierra Oncology to Neutral, Raises Price Target to $55
13 Apr 22
News, Downgrades, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis downgrades Sierra Oncology (NASDAQ:SRRA) from Buy to Neutral and raises the price target from $51 to $55.
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
13 Apr 22
Biotech, M&A, News, Penny Stocks, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
13 Apr 22
Biotech, M&A, News, Health Care, Small Cap, Movers, Trading Ideas, General
GSK Reached Agreement to Acquire Sierra Oncology For $55/Share
13 Apr 22
M&A, News, Small Cap
GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 pe

Press releases

From Benzinga Pro
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
17 Jun 22
Press Releases
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
26 May 22
Press Releases
– MOMENTUM data demonstrate potential use of momelotinib in myelofibrosis patients who are symptomatic and anemic – – Additional data highlight improved transfusion independence, symptoms and spleen volume of cytopenic
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
12 May 22
Press Releases
– Oral presentation of MOMENTUM pivotal phase 3 data in myelofibrosis patients who are symptomatic and anemic – – Poster presentation to highlight improved transfusion independence, symptoms and spleen volume of these
Sierra Oncology Reports First Quarter 2022 Results
6 May 22
Press Releases
Sierra Oncology, Inc. (NASDAQ:SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates BKI, SAIL, SRRA, ATRS
5 May 22
News, Legal, Press Releases
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
5 May 22
Press Releases
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Sierra Oncology, Inc (NASDAQGM:SRRA) to GlaxoSmithKline plc
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CMPI, SBOW, SRRA, ATRS
3 May 22
Small Cap, Press Releases
NEW YORK, May 3, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to
The M&A Class Action Firm Continues the Investigation of Sierra Oncology, Inc. - SRRA
2 May 22
M&A, Press Releases
NEW YORK, NY / ACCESSWIRE / May 2, 2022 /Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
2 May 22
Press Releases
Kuznicki Law PLLC is investigating the proposed sale of Sierra Oncology, Inc (NASDAQGM:SRRA) to GlaxoSmithKline plc (NYSE:GSK). Under the terms of the proposed transaction, shareholders of Sierra will receive only
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates SBOW, SAIL, SRRA, VWTR
29 Apr 22
Legal, Press Releases
NEW YORK, NY / ACCESSWIRE / April 29, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary
SHAREHOLDER ALERT: Weiss Law Reminds SRRA, HBP, EMCF, and VWTR Shareholders About Its Ongoing Investigations
28 Apr 22
Press Releases
NEW YORK, April 28, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PLAN, WAVD, SRRA, ATRS
28 Apr 22
Press Releases
NEW YORK, April 28, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
25 Apr 22
Press Releases
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Sierra Oncology, Inc (NASDAQGM:SRRA) to GlaxoSmithKline plc
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates TVTY, SRRA, ATRS, VWTR
21 Apr 22
Legal, Press Releases
NEW YORK, NY / ACCESSWIRE / April 21, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary
SHAREHOLDER ALERT: Weiss Law Reminds ATRS, SRRA, HBP, and EMCF Shareholders About Its Ongoing Investigations
20 Apr 22
Press Releases
NEW YORK, April 20, 2022 /PRNewswire/ -- If you own shares in any of the companies listed above and
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CDK, TUFN, SAIL, SRRA
19 Apr 22
News, Legal, Press Releases
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary
Investor Alert - The M&A Class Action Firm is Investigating the Merger - ATRS, SRRA, SAIL, MSP, CDK, VWTR
18 Apr 22
Press Releases
NEW YORK, April 18, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sierra Oncology, Inc. Buyout
18 Apr 22
Press Releases
Wilmington, Delaware--(Newsfile Corp. - April 18, 2022) - Rigrodsky Law, P.A. is investigating Sierra Oncology, Inc. ("Sierra") (NASDAQ:SRRA) regarding possible breaches of fiduciary duties and other violations of law
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates VWTR, ATRS, SBOW, SRRA
18 Apr 22
Press Releases
NEW YORK , April 18, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
14 Apr 22
Small Cap, Opinion, Press Releases
PALM BEACH, Fla., April 14, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - CAR-T therapy is a sort of treatment in which a patient's T cells which is a type of immune system cell, are genetically